Integra LifeSciences (NASDAQ:IART) Issues Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its third quarter 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.550-0.590 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $410.0 million-$412.0 million. Integra LifeSciences also updated its FY 2026 guidance to 2.300-2.400 EPS.

Integra LifeSciences Trading Down 1.2%

NASDAQ:IART opened at $16.09 on Friday. The business’s 50 day moving average is $16.83 and its two-hundred day moving average is $15.17. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $20.49. The company has a market cap of $1.25 billion, a PE ratio of -178.76, a P/E/G ratio of 0.84 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, analysts predict that Integra LifeSciences will post 2.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on IART shares. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Wall Street Zen cut shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Thursday, June 18th. Citigroup reissued a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, UBS Group began coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.